Trial Profile
Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS®Birch-Alder tablets for patients with tree pollen-induced allergic rhinoconjunctivitis A Phase III study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2015
Price :
$35
*
At a glance
- Drugs Tree pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Lofarma S.p.A
- 07 Jan 2014 New trial record